Ping Ke1,2, Bo-Zong Shao1, Zhe-Qi Xu1, Xiong-Wen Chen3, Wei Wei4, Chong Liu1. 1. Department of Pharmacology, Second Military Medical University, Shanghai, China. 2. Naval Convalescent Zone of Hangzhou Sanatorium, Nanjing Military Command, Hangzhou, China. 3. Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA, USA. 4. State Key Laboratory Breeding Base for Zhejiang Sustainable Plant Pest and Disease Control, Zhejiang Province Key Laboratory for Food Safety, Zhejiang Academy of Agricultural Sciences, Institute of Quality and Standard for Agro-products, Hangzhou, China.
Abstract
AIMS: To evaluate whether activating α7 nicotinic acetylcholine receptor (α7nAChR) could inhibit the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome through regulation of β-arrestin-1 in monocyte/macrophage system, thus contributing to the control of neuroinflammation. METHODS: The protein levels of NLRP3, caspase-1 (Casp-1) p20 and proCasp-1, interleukin-1β (IL-1β) p17 and proIL-1β, IL-18 and proIL-18 were measured using Western blotting. The mRNA levels of Casp-1 and IL-1β were detected by real-time PCR (RT-PCR). The colocalization and interaction of NLRP3 protein and β-arrestin-1 were measured by immunofluorescence staining and immunoprecipitation. RESULTS: The expression of β-arrestin-1 was significantly increased and colocalized with CD45-positive cells in spinal cord of experimental auto-immune encephalomyelitis (EAE) mice when compared with the sham mice, which was attenuated by pretreatment with PNU282987, a specific α7nAChR agonist. PNU282987 also significantly inhibited the activation of NLRP3 inflammasome and thus decreased the production of IL-1β and IL-18 both in lipopolysaccharide (LPS)/ATP-stimulated BV2 microglia in vitro and spinal cord from EAE mice in vivo, while inverse effects were observed in α7nAChR knockout mice. Furthermore, overexpression of β-arrestin-1 attenuated the inhibitory effect of PNU282987 on NLRP3 inflammasome activation in LPS/ATP-stimulated BV2 microglia. PNU282987 inhibited the interaction between β-arrestin-1 and NLRP3 protein in vitro. CONCLUSIONS: The present study demonstrates that activating α7nAChR can lead to NLRP3 inflammasome inhibition via regulation of β-arrestin-1 in monocyte/microglia system.
AIMS: To evaluate whether activating α7 nicotinic acetylcholine receptor (α7nAChR) could inhibit the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome through regulation of β-arrestin-1 in monocyte/macrophage system, thus contributing to the control of neuroinflammation. METHODS: The protein levels of NLRP3, caspase-1 (Casp-1) p20 and proCasp-1, interleukin-1β (IL-1β) p17 and proIL-1β, IL-18 and proIL-18 were measured using Western blotting. The mRNA levels of Casp-1 and IL-1β were detected by real-time PCR (RT-PCR). The colocalization and interaction of NLRP3 protein and β-arrestin-1 were measured by immunofluorescence staining and immunoprecipitation. RESULTS: The expression of β-arrestin-1 was significantly increased and colocalized with CD45-positive cells in spinal cord of experimental auto-immune encephalomyelitis (EAE) mice when compared with the sham mice, which was attenuated by pretreatment with PNU282987, a specific α7nAChR agonist. PNU282987 also significantly inhibited the activation of NLRP3 inflammasome and thus decreased the production of IL-1β and IL-18 both in lipopolysaccharide (LPS)/ATP-stimulated BV2 microglia in vitro and spinal cord from EAE mice in vivo, while inverse effects were observed in α7nAChR knockout mice. Furthermore, overexpression of β-arrestin-1 attenuated the inhibitory effect of PNU282987 on NLRP3 inflammasome activation in LPS/ATP-stimulated BV2 microglia. PNU282987 inhibited the interaction between β-arrestin-1 and NLRP3 protein in vitro. CONCLUSIONS: The present study demonstrates that activating α7nAChR can lead to NLRP3 inflammasome inhibition via regulation of β-arrestin-1 in monocyte/microglia system.
Authors: María José Mansilla; Carla Sellès-Moreno; Sara Fàbregas-Puig; Joan Amoedo; Juan Navarro-Barriuso; Aina Teniente-Serra; Laia Grau-López; Cristina Ramo-Tello; Eva M Martínez-Cáceres Journal: CNS Neurosci Ther Date: 2014-11-18 Impact factor: 5.243
Authors: Adriel S Moraes; Rosemeire F O Paula; Fernando Pradella; Mariana P A Santos; Elaine C Oliveira; Felipe von Glehn; Daniela S Camilo; Helder Ceragioli; Alfredo Peterlevitz; Vitor Baranauskas; Walkyria Volpini; Alessandro S Farias; Leonilda M B Santos Journal: CNS Neurosci Ther Date: 2013-06-03 Impact factor: 5.243
Authors: Chong Liu; Fu-Ming Shen; Ying-Ying Le; Yan Kong; Xia Liu; Guo-Jun Cai; Alex F Chen; Ding-Feng Su Journal: Crit Care Med Date: 2009-02 Impact factor: 7.598
Authors: Kiichi Nakahira; Jeffrey Adam Haspel; Vijay A K Rathinam; Seon-Jin Lee; Tamas Dolinay; Hilaire C Lam; Joshua A Englert; Marlene Rabinovitch; Manuela Cernadas; Hong Pyo Kim; Katherine A Fitzgerald; Stefan W Ryter; Augustine M K Choi Journal: Nat Immunol Date: 2010-12-12 Impact factor: 25.606
Authors: Amol A Kulkarni; Ayyiliath M Sajith; Trevor T Duarte; Anahis Tena; Charles T Spencer; J Phillip Bowen Journal: Med Chem Res Date: 2019-11-14 Impact factor: 1.965
Authors: Dilyara Nurkhametova; Andrei Siniavin; Maria Streltsova; Denis Kudryavtsev; Igor Kudryavtsev; Raisa Giniatullina; Victor Tsetlin; Tarja Malm; Rashid Giniatullin Journal: Front Cell Neurosci Date: 2020-10-28 Impact factor: 5.505
Authors: Sarah E Webster; Nathan C Sklar; Jake B Spitsbergen; Megan L Stanchfield; Mark K Webster; David M Linn; Deborah C Otteson; Cindy L Linn Journal: Exp Eye Res Date: 2021-08-01 Impact factor: 3.770